Early-Stage HCC Detection Using Multi-Gene Methylation Scoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting hepatocellular carcinoma (HCC) are limited by low sensitivity and specificity, particularly in early stages, and existing biomarkers like serum alpha-fetoprotein (AFP) have significant limitations, necessitating the development of more accurate diagnostic tools.
Innovation Solution
A method utilizing differentially methylated genes (APC, COX2, miR-203, RASSF1A, VIM, RGS10, ST8SIA6, and miR-129-2) as biomarkers, measured through quantitative methylation-specific PCR (qMSP), calculates an M-score for early-stage HCC detection, enhancing diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum alpha-fetoprotein (AFP) is used as a tumor marker for screening and monitoring HCC, then the method is simple and widely available, but the sensitivity and specificity are insufficient particularly in early stages
Solution Approach 1:
The patent segments the detection process into multiple independent measurement components: detecting methylation levels of multiple specific genes (RASSF1A, APC, VIM, RGS10, ST8SIA6, COX2, miR-203, miR-129-2) rather than relying on a single marker. Each gene's methylation level is measured separately using qMSP, then integrated through a scoring system to achieve high detection accuracy while maintaining procedural clarity
Solution Approach 2:
The patent creates a composite diagnostic approach by combining multiple gene methylation markers into a unified detection system. The M-score integrates methylation levels from eight different genes, each contributing unique diagnostic information, thereby achieving superior sensitivity and specificity compared to individual markers while providing a comprehensive early-stage HCC detection capability
2Reliability
If traditional single-marker methods are used for HCC detection, then the detection process is simple, but the sensitivity and specificity remain low especially for early-stage detection
Solution Approach 1:
The detection system is segmented into distinct functional components: sample preparation, bisulfite conversion, qMSP amplification for each gene target, and M-score calculation. This segmentation allows each component to be optimized independently while maintaining overall system reliability through the coordinated function of multiple gene-specific assays
Solution Approach 2:
The patent implements preliminary action through the standardized preparation and validation of multiple gene-specific assays before clinical application. The methylation-specific PCR primers and probes for all eight genes are pre-designed and validated, allowing the system to achieve high diagnostic reliability from the outset rather than requiring iterative optimization during patient testing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The M-score significantly improves the detection of early-stage HCC, outperforming traditional markers like AFP, with higher sensitivity and specificity, enabling more effective early intervention.
Implementation Method 1
DNA methyltransferases catalyze the addition of a methyl group to the carbon-5 position of cytosine residues in CpG dinucleotides. This methylation of the promoter or 5′ region of CpG islands can lead to the transcriptional repression of downstream genes.
Implementation Method 2
performing quantitative measurement of the methylation levels of a plurality of biomarkers selected from the group of differentially methylated genes with quantitative methylation-specific PCR (qMSP)
Data Source
AI summary
A method of detecting early-stage hepatocellular carcinoma has steps of performing biomarker identification of a plurality of differentially methylated genes in a computing system; performing quantitative measurement of the methylation levels of the biomarkers selected from the group of differentially methylated genes with quantitative methylation-specific PCR in the computing system; performing calculation of a formula in the computing system to obtain M-score of the selected biomarkers according to the measured methylation levels of the selected biomarkers with a logistic regression analysis; and performing a risk level evaluation of liver cancer with the M-score of the selected biomarkers in the computing system.